CKDXF OTC
Ceryvyn Therapeutics Limited
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: -97.7%
1Y: -97.7%
3Y: -97.6%
5Y: -99.1%
$0.01
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$9M
+94.6% ▲
Capital Expenditures
$0
+100.0% ▲
Free Cash Flow
-$9M
+94.6% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$28M
+77.6% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$128M | -$212M | -$220M | $0 | $229M |
| Depreciation & Amort. | $108K | $150K | $105K | $0 | $0 |
| Stock-Based Comp. | $5M | $6M | $5M | $0 | $0 |
| Change in Working Capital | $20M | $21M | $17M | -$25M | -$2M |
| Other Non-Cash Items | $10M | $12M | $46M | -$133M | -$235M |
| Operating Cash Flow | -$98M | -$179M | -$161M | -$159M | -$9M |
| — Investing Activities — | |||||
| Capital Expenditures | -$23K | -$33K | -$33K | -$13K | $0 |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | $0 | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | $0 | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$23K | -$33K | -$33K | -$13K | $0 |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | -$71K | -$89K | -$93K | -$21M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$183K | -$35K | $85M | $51K | $0 |
| Financing Cash Flow | $237K | $249M | $244M | $35M | -$21M |
| Net Change in Cash | -$93M | $69M | $83M | -$124M | -$28M |
| Cash End of Period | $65M | $134M | $172M | $48M | $21M |
| Free Cash Flow | -$98M | -$179M | -$161M | -$159M | -$9M |